Key result
Study diversity warrants caution when linking rosiglitazone to myocardial infarction and cardiac death.
Why the study?
The recent fixed-effects meta-analysis of rosiglitazone's association with myocardial infarction and cardiac death raised concerns due to diverse study designs and data interpretation challenges.
Caution warranted for fixed-effects rosiglitazone meta-analyses; challenges MI and cardiac death inferences amid design heterogeneity.
We read with interest the recent fixed-effects meta-analysis of the connection between rosiglitazone and both myocardial infarction and cardiac death and the lessons garnered from the Food and Drug Administration Advisory Meeting (1,2). We urge caution in data interpretation. Due to the diversity of the designs (eligibility, doses, duration of follow-up, concomitant medications), we view fixed-effects …
No takes yet. Share an insight, caveat, or question.
Shuster et al. (2008) conducted a letter in Myocardial infarction and cardiac death. Rosiglitazone was evaluated on Myocardial infarction and cardiac death. The authors urge caution in interpreting the fixed-effects meta-analysis linking rosiglitazone to myocardial infarction and cardiac death due to significant diversity in study designs.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: